Acura To Launch Nexafed PSE Despite Limits Of Extraction Resistance

The spread of “one-pot” meth manufacturing will not deter Acura Pharmaceuticals from launching its OTC extraction-resistant PSE product, Nexafed. Making PSE products available in an extraction-resistant delivery formulation could offer an alternative to moving all dosages of the ingredient to the Rx class.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America